These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 22917248)

  • 1. Flexible or fixed: a comparative review of linear and cyclic cancer-targeting peptides.
    Roxin Á; Zheng G
    Future Med Chem; 2012 Aug; 4(12):1601-18. PubMed ID: 22917248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of side-chain cyclization in determining the receptor-bound conformation of peptides: cyclic tripeptides and angiotensin II.
    Kataoka T; Beusen DD; Clark JD; Yodo M; Marshall GR
    Biopolymers; 1992 Nov; 32(11):1519-33. PubMed ID: 1333831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanocortin-1 receptor-targeting with radiolabeled cyclic α-melanocyte-stimulating hormone analogs for melanoma imaging.
    Raposinho PD; Correia JD; Oliveira MC; Santos I
    Biopolymers; 2010; 94(6):820-9. PubMed ID: 20564045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity and stability of human kallikrein-2-specific linear and cyclic peptide inhibitors.
    Pakkala M; Hekim C; Soininen P; Leinonen J; Koistinen H; Weisell J; Stenman UH; Vepsäläinen J; Närvänen A
    J Pept Sci; 2007 May; 13(5):348-53. PubMed ID: 17436344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative comparison of the relative cell permeability of cyclic and linear peptides.
    Kwon YU; Kodadek T
    Chem Biol; 2007 Jun; 14(6):671-7. PubMed ID: 17584614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering cyclic peptide toxins.
    Clark RJ; Craik DJ
    Methods Enzymol; 2012; 503():57-74. PubMed ID: 22230565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designing Cell-Permeable Macrocyclic Peptides.
    Appiah Kubi G; Dougherty PG; Pei D
    Methods Mol Biol; 2019; 2001():41-59. PubMed ID: 31134566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of cyclic and branched peptide analogues as ligands for cholecystokinin type 1 receptor.
    De Luca S; De Capua A; Saviano M; Della Moglie R; Aloj L; Tarallo L; Pedone C; Morelli G
    Bioorg Med Chem; 2007 Sep; 15(17):5845-53. PubMed ID: 17562367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic cancer targeting peptides.
    Aina OH; Sroka TC; Chen ML; Lam KS
    Biopolymers; 2002; 66(3):184-99. PubMed ID: 12385037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histidine-iridium(III) coordination-based peptide luminogenic cyclization and cyclo-RGD peptides for cancer-cell targeting.
    Ma X; Jia J; Cao R; Wang X; Fei H
    J Am Chem Soc; 2014 Dec; 136(51):17734-7. PubMed ID: 25486120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoselective cyclization of unprotected linear peptides by α-ketoacid-hydroxylamine amide-ligation.
    Fukuzumi T; Ju L; Bode JW
    Org Biomol Chem; 2012 Aug; 10(30):5837-44. PubMed ID: 22426859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cyclization of peptides and depsipeptides.
    Davies JS
    J Pept Sci; 2003 Aug; 9(8):471-501. PubMed ID: 12952390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-reactive binding of cyclic peptides to an anti-TGFalpha antibody Fab fragment: an X-ray structural and thermodynamic analysis.
    Hahn M; Winkler D; Welfle K; Misselwitz R; Welfle H; Wessner H; Zahn G; Scholz C; Seifert M; Harkins R; Schneider-Mergener J; Höhne W
    J Mol Biol; 2001 Nov; 314(2):293-309. PubMed ID: 11718562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and cytotoxicity of the depsipeptides analogues of callipeltin B.
    Kikuchi M; Watanabe Y; Tanaka M; Akaji K; Konno H
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4865-8. PubMed ID: 21741837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and biological evaluation of linear and cyclic phosphopeptide ligands of the N-terminal SH2 domain of protein tyrosine phosphatase SHP-1.
    Imhof D; Wieligmann K; Hampel K; Nothmann D; Zoda MS; Schmidt-Arras D; Zacharias M; Böhmer FD; Reissmann S
    J Med Chem; 2005 Mar; 48(5):1528-39. PubMed ID: 15743195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor-mediated tumor targeting with radiopeptides. Part 1. General principles and methods.
    Eberle AN; Mild G
    J Recept Signal Transduct Res; 2009; 29(1):1-37. PubMed ID: 19519167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adsorption behavior of linear and cyclic genetically engineered platinum binding peptides.
    Seker UO; Wilson B; Dincer S; Kim IW; Oren EE; Evans JS; Tamerler C; Sarikaya M
    Langmuir; 2007 Jul; 23(15):7895-900. PubMed ID: 17579466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclic peptides as potential therapeutic agents for skin disorders.
    Namjoshi S; Benson HA
    Biopolymers; 2010; 94(5):673-80. PubMed ID: 20564043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of backbone versus side chain peptide cyclization: application for HIV-1 integrase inhibitors.
    Hayouka Z; Levin A; Hurevich M; Shalev DE; Loyter A; Gilon C; Friedler A
    Bioorg Med Chem; 2012 May; 20(10):3317-22. PubMed ID: 22507205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sortase A as a tool for high-yield histatin cyclization.
    Bolscher JG; Oudhoff MJ; Nazmi K; Antos JM; Guimaraes CP; Spooner E; Haney EF; Garcia Vallejo JJ; Vogel HJ; van't Hof W; Ploegh HL; Veerman EC
    FASEB J; 2011 Aug; 25(8):2650-8. PubMed ID: 21525488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.